Sugi Predict

Sugi Predict / Compounds / SCHEMBL989398

SCHEMBL989398

SCHEMBL989398

COC(=O)c1ccc(C(C)=O)cn1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 2/20 0.79
▸ KDM4E B2RXH2 2/20 0.64
▸ L3MBTL1 Q9Y468 1/20 0.64
▸ MEN1 O00255 1/20 0.48
▸ AHR P35869 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ P4HTM Q9NXG6 4/20 0.46
▸ P4HA1 P13674 1/20 0.46
▸ MIF P14174 1/20 0.46
▸ POLB P06746 2/20 0.43
▸ MAPT P10636 2/20 0.43
▸ LCK P06239 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.42
▸ CA12 O43570 1/20 0.42
▸ CA1 P00915 1/20 0.42
▸ CA2 P00918 1/20 0.42
▸ CA7 P43166 1/20 0.42
▸ CA9 Q16790 1/20 0.42
▸ CA14 Q9ULX7 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL69747 0.89 MAPK1 (1.00) MAPK1KDM4EL3MBTL1MEN1AHR
SCHEMBL29508473 0.89 MAPK1 (1.00) MAPK1KDM4EL3MBTL1MEN1AHR
SCHEMBL7882276 0.86 MAPK1 (0.74) MAPK1KDM4EL3MBTL1MEN1AHR
SCHEMBL64024 0.85 MAPK1 (0.79) MAPK1KDM4EL3MBTL1P4HTMP4HA1
SCHEMBL29826109 0.85 MAPK1 (0.79) MAPK1KDM4EL3MBTL1P4HTMP4HA1
SCHEMBL423045 0.85 MAPK1 (0.79) MAPK1KDM4EL3MBTL1MEN1AHR
SCHEMBL1019173 0.84 MAPK1 (0.77) MAPK1KDM4EL3MBTL1MEN1AHR
SCHEMBL8251331 0.84 MAPK1 (0.77) MAPK1KDM4EL3MBTL1P4HTMP4HA1
SCHEMBL30401004 0.84 MAPK1 (0.77) MAPK1KDM4EL3MBTL1MEN1AHR
SCHEMBL14234693 0.82 MAPK1 (0.80) MAPK1KDM4EL3MBTL1MEN1AHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240287070-A1 FUSED HETEROCYCLIC DERIVATIVES JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) 2024-08-29 — — US disclosed
EP-4347590-A1 FUSED HETEROCYCLIC DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2024-04-10 — — EP disclosed
CN-117715909-A Condensed heterocyclic derivative 杨森科学爱尔兰无限公司 2024-03-15 — — CN disclosed
WO-2022253259-A1 FUSED HETEROCYCLIC DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2022-12-08 — — WO disclosed
US-9809586-B2 Inhibitors of collagen prolyl 4-hydroxylase WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2017-11-07 — — US disclosed
EP-2536276-B1 NOVEL BEXAROTENE ANALOGS UNIV ARIZONA (US) 2016-11-23 — — EP disclosed
US-20160280701-A1 INHIBITORS OF COLLAGEN PROLYL 4-HYDROXYLASE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-09-29 — — US disclosed
US-20160221948-A1 NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-08-04 — — US disclosed
US-8598355-B2 Amide compound ASTELLAS PHARMA INC. (JP) 2013-12-03 — — US disclosed
EP-2565191-A1 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy Astellas Pharma Inc. (JP) 2013-03-06 — — EP disclosed
WO-2012068210-A1 PYRIDYL-THIAZOLYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION JANSSEN PHARMACEUTICA NV (BE) 2012-05-24 — — WO disclosed
US-20120129843-A1 PYRIDYL-THIAZOLYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION JANSSEN PHARMACEUTICA N.V. (BE) 2012-05-24 — — US disclosed
US-20110144153-A1 AMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-06-16 — — US disclosed
US-20110144153-A1 AMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-06-16 — — US disclosed
US-20110144153-A1 AMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-06-16 — — US disclosed
CN-102026961-A Amide compound ASTELLAS PHARMA INC 2011-04-20 — — CN disclosed
EP-2277858-A1 AMIDE COMPOUND Astellas Pharma Inc. (JP) 2011-01-26 — — EP disclosed
WO-2009139373-A1 AMIDE COMPOUND アステラス製薬株式会社 (JP) 2009-11-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287070-A1 FUSED HETEROCYCLIC DERIVATIVES HAVCR2, HCCS, GOT2 MAPK1 4056/4885KDM4E 3515/4885L3MBTL1 4523/4885
US-20160221948-A1 NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-4, HRH4 MAPK1 2112/4885KDM4E 1433/4885L3MBTL1 3579/4885
US-20120129843-A1 PYRIDYL-THIAZOLYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION MMP1, MMP9, TIMP3 MAPK1 1587/4885KDM4E 1762/4885L3MBTL1 1431/4885
US-20110144153-A1 AMIDE COMPOUND PTGER4, PTGER1, PTGER2 MAPK1 3300/4885KDM4E 959/4885L3MBTL1 4508/4885
US-20160280701-A1 INHIBITORS OF COLLAGEN PROLYL 4-HYDROXYLASE P4HA1, EGLN3, P4HTM MAPK1 3972/4885KDM4E 880/4885L3MBTL1 2515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.